Published in Cancer Weekly, January 11th, 2000
Research has demonstrated the overexpression of the RI(alpha) subunit of cAMP-dependent protein kinase (PKA) in several human cancers. As such, PKA has been suggested as a potential target for anticancer strategies.
Hui Wang and colleagues from the University of Alabama, and Hybridon, Inc., Massachusetts, evaluated an anti-PKA antisense oligonucleotide (mixed backbone oligonucleotide [MBO]) as a therapeutic approach to human cancer. Data from their study was published in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.